Related Experiment Video
Updated: Oct 31, 2025

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
The role of ADAM17 during liver damage
Mazin Al-Salihi1,2, Anna Bornikoel1, Yuan Zhuang1
1Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, Universitätsstr. 1, D-40225 Düsseldorf, Germany.
Abstract:
A disintegrin and metalloprotease (ADAM) 17 is a membrane bound protease, involved in the cleavage and thus regulation of various membrane proteins, which are critical during liver injury. Among ADAM17 substrates are tumor necrosis factor α (TNFα), tumor necrosis factor receptor 1 and 2 (TNFR1, TNFR2), the epidermal growth factor receptor (EGFR) ligands amphiregulin (AR) and heparin-binding-EGF-like growth factor (HB-EGF), the interleukin-6 receptor (IL-6R) and the receptor for a hepatocyte growth factor (HGF), c-Met. TNFα and its binding receptors can promote liver injury by inducing apoptosis and necroptosis in liver cells. Consistently, hepatocyte specific deletion of ADAM17 resulted in increased liver cell damage following CD95 stimulation. IL-6 trans-signaling is critical for liver regeneration and can alleviate liver damage. EGFR ligands can prevent liver damage and deletion of amphiregulin and HB-EGF can result in increased hepatocyte death and reduced proliferation. All of which indicates that ADAM17 has a central role in liver injury and recovery from it. Furthermore, inactive rhomboid proteins (iRhom) are involved in the trafficking and maturation of ADAM17 and have been linked to liver damage. Taken together, ADAM17 can contribute in a complex way to liver damage and injury.
Insights
ADAM17 regulates key proteins in liver injury. Its deletion worsens liver damage, while its substrates like EGFR ligands aid recovery, highlighting ADAM17
Area of Science:
- Hepatology
- Molecular Biology
- Cellular Signaling
Background:
- ADAM17 is a metalloprotease regulating membrane proteins crucial in liver injury.
- ADAM17 substrates include TNFα, EGFR ligands (AR, HB-EGF), IL-6R, and c-Met, impacting liver cell fate.
- Inactive rhomboid proteins (iRhoms) influence ADAM17 function and are linked to liver damage.
Purpose of the Study:
- To elucidate the complex role of ADAM17 in liver injury and regeneration.
- To understand how ADAM17 substrates contribute to or protect against liver damage.
- To investigate the involvement of iRhoms in ADAM17-mediated liver pathology.
Main Methods:
- Analysis of ADAM17 substrate cleavage and function in liver injury models.
- Investigation of hepatocyte-specific ADAM17 deletion effects on liver damage.
- Examination of the impact of EGFR ligands and IL-6 signaling on liver recovery.
Main Results:
- ADAM17 deletion exacerbates liver cell damage, particularly after CD95 stimulation.
- EGFR ligands (AR, HB-EGF) demonstrate protective effects, preventing hepatocyte death and promoting proliferation.
- IL-6 trans-signaling is vital for liver regeneration and mitigating damage.
Conclusions:
- ADAM17 plays a central, multifaceted role in both the pathogenesis and resolution of liver injury.
- Dysregulation of ADAM17 and its substrates significantly impacts liver cell survival, apoptosis, and regeneration.
- Targeting ADAM17 or its pathways may offer therapeutic strategies for liver diseases.
Related Concept Videos
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

